Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: A randomized, placebo-controlled study

International Clinical Psychopharmacology

Volumn 26, Issue 4, 2011, Pages 201-205

  Altamura, Alfredo Carlo ^a   Serati, Marta ^a   Buoli, Massimiliano ^a   Dell'Osso, Bernardo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Augmentation; Generalized anxiety disorder; Quetiapine

Indexed keywords

CITALOPRAM; ESCITALOPRAM; PAROXETINE; PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 80051544741     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283457d73     Document Type: Article

References (38)

1. Allgulander C (2010). Novel approaches to treatment of generalized anxiety disorder. Curr Opin Psychiatry 23:37-42.
2. Altamura AC, Dell'Osso B, D'Urso N, Russo M, Fumagalli S, Mundo E (2008). Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectr 13:415-422. (Pubitemid 351792224)
3. Altamura AC, Buoli M, Albano A, Dell'Osso B (2010). Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study. Int Clin Psychopharmacol 25:172-179.
4. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders. Text Revision. 4th edition. Washington DC: American Psychiatric Association.
5. Baldwin DS, Tiwari N (2009). The pharmacologic treatment of patients with generalized anxiety disorder: where are we now and where are we going? CNS Spectr 14:5-12.
6. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al.; British Association for Psychopharmacology (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-596.
7. Baldwin DS, Khalil IA, Garner M (2010). Pharmacological treatment of generalized anxiety disorder. Curr Topics Behav Neurosci 2:453-467.
8. Ballenger JC (1999). Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 60:29-34. (Pubitemid 30107953)
9. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H (2010). Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13:305-320.
10. Dell'Osso B, Mundo E, Altamura AC (2006). Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessivecompulsive disorder: a six-month follow-up case series. CNS Spectr 11:879-883. (Pubitemid 44845665)
11. Dell'Osso B, Buoli M, Baldwin DS, Altamura AC (2010). Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Hum Psychopharmacol 25:17-29.
12. Figueroa C, Brecher M, Hamer-Maansson JE, Winter H (2009). Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 33: 199-204.
13. First MB,Williams JB, Gibbon M, Spitzer RL (1997). Structured clinical interview for DSM-IV axis I (SCID-I), clinician version. Washington DC: American Psychiatric Press.
14. First MB, Gibbon M, Spitzer RL, Williams JB, Benjamin LS (1997). Structured clinical interview for DSM-IV axis II personality disorders (SCID-II). Washington DC: American Psychiatric Press.
15. Gao K, Muzina D, Gajwani P, Calabrese JR (2006). Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry 67:1327-1340. (Pubitemid 44583379)
16. Gao K, Sheehan DV, Calabrese JR (2009). Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 9:1147-1158.
17. Garakani A, Mathew SJ, Charney DS (2006). Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med 73:941-949. (Pubitemid 46040391)
18. Glennon RA, Darmani NA, Martin BR (1991). Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents. Life Sci 48:2493-2498.
19. Guy Wr (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, US: Department of Health, Education, and Welfare.
20. Hamilton M (1959). The assessment of anxiety states by rating. Br J Psychiatry 32:50.
21. Hoge EA, Worthington JJ III, Kaufman RE, Delong HR, Pollack MH, Simon NM (2008). Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr 13:522-527. (Pubitemid 351960777)
22. Hood SD, Melichar JK, Taylor LG, Kalk N, Edwards TR, Hince DA, et al. (2010). Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. J Psychopharmacol 25:78-86. In press.
23. Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, et al. (2008). Quetiapine as an adjunctive pharmacotherapy for the treatment of nonremitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord 22:1480-1486.
24. Koponen H, Allgulander C, Erickson J (2007). Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. J Clin Psychiatry 9: 100-107. (Pubitemid 46607463)
25. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008). N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33:2303-2312.
26. Lieb R, Becker E, Altamura AC (2005). The epidemiology of generalized anxiety disorder. European Neuropsychopharmacology 15:445-452.
27. Lohoff FW, Etemad B, Mandos LA, Gallop R, Rickels K (2010). Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol 30:185-189.
28. Lorenz RA, Jackson CW, Saitz M (2010). Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy 30:942-951.
29. Menezes GB, Fontenelle LF, Mululo S, Versiani M (2007). Treatment-resistant anxiety disorders: social phobia, generalized anxiety disorder and panic disorder. Rev Bras Psiquiatr 29S2:S55-S60.
30. Miceli JJ, Ramey TS,Weaver JJ, Gleit JA, Knapp L (2009). Adjunctive pregabalin treatment after partial response in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. In: Proceedings of 162nd Annual Meeting of the American Psychiatric Association; 16-21 May 2009; San Francisco, CA: American Psychiatric Association.
31. Pezze MA, Feldon J (2004). Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol 74:301-320. (Pubitemid 39586721)
32. Pollack MH, Matthews J, Scott EL (1998). Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 155:992-993. (Pubitemid 28307619)
33. Pollack MH, Simon NM, Zalta AK (2006). Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 59:211-215. (Pubitemid 43208966)
34. Ravindran LN, Stein MB (2010). The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 71:839-854.
35. Schwartz TL (2002). The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull 36:53-57.
36. Simon NM (2009). Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse. J Clin Psychiatry 70S2:10-14.
37. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH (2006). An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67:381-385.
38. Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ III, Zhang W, et al. (2008). Quetiapine augmentation of paroxetine CR for the treatment of generalized anxiety disorder: preliminary findings. Psychopharmacol (Berl) 197:675-681.